Seres Therapeutics Inc (NAS:MCRB)
$ 0.7589 -0.017 (-2.19%) Market Cap: 114.94 Mil Enterprise Value: 221.66 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 49/100

Seres Therapeutics, Inc. - Special Call Transcript

Aug 10, 2020 / 12:30PM GMT
Release Date Price: $22.7 (+389.22%)
Operator

Good day, ladies and gentlemen, and welcome to the Seres Therapeutics Phase III Update Call.

(Operator Instructions) As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Mr. Carlo Tanzi, Head of Investor Relations.

Carlo Tanzi
Seres Therapeutics, Inc. - VP of IR & Corporate Communications

Thank you, and good morning. Our press release and accompanying slide presentation, with the positive results of the company's SER-109 Phase III study and a business update, became available earlier this morning and can be found on the Investors and Media section of the company's website.

I'd like to remind you that we will be making forward-looking statements relating to the SER-109 regulatory approval time line, the market and commercial opportunity for SER-109, the potential for SER-109 to transform the treatment of recurrent CDI, the need for additional safety data to support regulatory approval, the validation of Seres' platform and its impact on a broad range of diseases. Actual results

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot